Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma

被引：9

作者：

Lei, Zhengqing ^{[1
]}

Ma, Weihu ^{[1
]}

Si, Anfeng ^{[2
]}

Zhang, Yuhua ^{[3
]}

Yang, Facai ^{[1
]}

Yu, Qiushi ^{[1
]}

Tang, Haolan ^{[1
]}

Xiao, Qianru ^{[1
]}

Zhou, Jiahua ^{[1
]}

Wang, Kui ^{[4
]}

Tang, Yufu ^{[5
]}

Han, Tao ^{[6
]}

Yin, Guowen ^{[7
]}

Chen, Jinhong ^{[8
,9
]}

Liu, Xiufeng ^{[10
]}

Zhao, Hua ^{[11
]}

Yu, Decai ^{[12
]}

Luo, Tao ^{[13
,14
]}

Wang, Qing ^{[15
]}

Yan, Maolin ^{[16
]}

Mao, Xianhai ^{[17
]}

Li, Jing ^{[18
]}

Wang, Kai ^{[19
]}

Li, Jingdong ^{[20
]}

Zeng, Yongyi ^{[21
]}

Ding, Dequan ^{[22
]}

Chen, Tingsong ^{[23
]}

Wu, Xiaofeng ^{[24
]}

Xia, Yongxiang ^{[24
]}

Wang, Kang ^{[25
]}

Guo, Weixing ^{[25
]}

Zhu, Guangyu ^{[26
]}

Gao, Shan ^{[27
]}

Hueser, Norbert ^{[28
]}

Lau, Wan Y. ^{[29
]}

Song, Tianqiang ^{[30
]}

Cheng, Shuqun ^{[25
]}

Shen, Feng ^{[31
]}

Cheng, Zhangjun ^{[1
]}

机构：

[1] Southeast Univ, Zhongda Hosp, Hepatopancreatobiliary Ctr, Sch Med, Nanjing 210009, Peoples R China

[2] Nanjing Med Univ, Dept Surg Oncol, Qin Huai Med Dist, Jinling Hosp, Nanjing, Peoples R China

[3] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Surg,Inst Basic Med, Hangzhou, Peoples R China

[4] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 2, Shanghai, Peoples R China

[5] Northern Theater Command, Dept Hepatobiliary Surg, Gen Hosp, Shenyang, Peoples R China

[6] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China

[7] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Intervent Radiol Dept,Affiliated Canc Hosp, Nanjing, Peoples R China

[8] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China

[9] Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China

[10] Jinling Hosp, Dept Med Oncol, PLA Canc Ctr, Nanjing, Peoples R China

[11] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou, Peoples R China

[12] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing, Peoples R China

[13] Third Mil Med Univ, Army Med Univ, Inst Pathol, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing, Peoples R China

[14] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Chongqing, Peoples R China

[15] Zibo Cent Hosp, Dept Gen Surg, Zibo, Peoples R China

[16] Fujian Prov Hosp, Dept Hepatobiliary Pancreat Surg, Fuzhou, Peoples R China

[17] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Hepatobiliary Surg, Affiliated Hosp 1, Changsha, Peoples R China

[18] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing, Peoples R China

[19] Nanchang Univ, Jiangxi Prov Clin Res Ctr Gen Surg Dis, Dept Gen Surg, Affiliated Hosp 2, Nanchang, Peoples R China

[20] North Sichuan Med Coll, Dept Hepatobiliary Surg, Affiliated Hosp, Nanchong, Peoples R China

[21] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary Surg, Fuzhou, Peoples R China

[22] Maanshan Peoples Hosp, Dept Intervent Radiol, Maanshan, Peoples R China

[23] Shanghai Univ Tradit Chinese Med, Dept Oncol, Peoples Hosp 7, Shanghai, Peoples R China

[24] Nanjing Med Univ, Chinese Acad Med Sci, Hepatobiliary Ctr, Affiliated Hosp 1,Key Lab Liver Transplantat,NHC K, Nanjing, Peoples R China

[25] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China

[26] Southeast Univ, Zhongda Hosp, Ctr Intervent Radiol & Vasc Surg, Sch Med,Dept Radiol, Nanjing, Peoples R China

[27] Southeast Univ, Zhongda Hosp, Adv Inst Life & Hlth, Sch Life Sci & Technol, Nanjing, Peoples R China

[28] Tech Univ Munich, TUM Sch Med, Dept Surg, Klinikum Rechts Isar, Munich, Germany

[29] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[30] Tianjin Med Univ Canc Inst & Hosp, Liver Canc Ctr, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China

[31] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 200438, Peoples R China

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 58卷 / 06期

基金：

中国国家自然科学基金;

关键词：

chemotherapy; combination therapy; immune checkpoint inhibitor; immunotherapy; intrahepatic cholangiocarcinoma; HEPATOCELLULAR-CARCINOMA; OPEN-LABEL; PLUS; BEVACIZUMAB;

D O I：

10.1111/apt.17623

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC).Aim: To compare the effect of different anti-PD-1 combination therapies as the first-line treatments for uICC.Methods: This study included 318 patients who received chemotherapy alone (Chemo), anti-PD-1 plus chemotherapy (ICI-chemo), anti-PD-1 plus targeted therapy (ICI-target) or anti-PD-1 plus targeted therapy and chemotherapy (ICI-target-chemo) as first line for uICC from 22 centres in China. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and safety.Results: Patients with ICI-chemo (median PFS [mPFS], 6.3 months; HR: 0.61, 95% CI: 0.42-0.88; p = 0.008; median OS [mOS], 10.7 months; HR: 0.61, 95% CI: 0.39-0.94; p = 0.026), ICI-target (7.2 months; HR: 0.54, 95% CI: 0.36-0.80; p = 0.002; 15.8 months; HR: 0.54, 95% CI: 0.35-0.84; p = 0.006) or ICI-target-chemo (6.9 months; HR: 0.65, 95% CI: 0.47-0.90; p = 0.009; 14.4 months; HR: 0.47, 95% CI: 0.31-0.70; p < 0.001) achieved better clinical outcomes than those with Chemo (3.8 months; 9.3 months). ICI-target was not inferior to ICI-chemo in survival outcomes (HR for PFS: 0.88, 95% CI: 0.55-1.42; p = 0.614; HR for OS: 0.89, 95% CI: 0.51-1.55; p = 0.680). ICI-target-chemo yielded similar prognoses as ICI-chemo (HR for PFS: 1.07, 95% CI: 0.70-1.62; p = 0.764; HR for OS: 0.77, 95% CI: 0.45-1.31; p = 0.328) and ICI-target (HR for PFS: 1.20, 95% CI: 0.77-1.88; p = 0.413; HR for OS: 0.86, 95% CI: 0.51-1.47; p = 0.583) but resulted in more adverse events (p < 0.001; p = 0.010). Multivariable and propensity score analyses supported these findings.Conclusions: Among patients with uICC, ICI-chemo or ICI-target provided more survival benefits than Chemo while achieving comparable prognoses and fewer adverse events than ICI-target-chemo.

引用

页码：611 / 622

页数：12

共 50 条

[21] PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, Lingyu
Ma, Jiaqiang
Ma, Lijie
Zheng, Bohao
Liu, Longzi
Song, Danjun
Wang, Yining
Zhang, Zhao
Gao, Qiang
Song, Kang
Wang, Xiaoying
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[22] Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review
Yang, Linda
Shan, Jocelyn
Shan, Leonard
Saxena, Akshat
Bester, Lourens
Morris, David L.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (05) : 570 - 588
[23] Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma
Seidensticker, Ricarda
Seidensticker, Max
Doegen, Kathleen
Mohnike, Konrad
Schuette, Kerstin
Stuebs, Patrick
Kettner, Erika
Pech, Maciej
Amthauer, Holger
Ricke, Jens
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
[24] TRANS-ARTERIAL EMBOLISATION THERAPIES FOR UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA: A SYSTEMATIC REVIEW
Shan, Jocelyn
Yang, Linda
Shan, Jocelyn
Shan, Leonard
Saxena, Akshat
Morris, David
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 187 - 187
[25] Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review
Zhang, Haitao
Han, Cuiping
Zheng, Xiaohuan
Zhao, Wenhua
Liu, Yuanshui
Ye, Xin
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 1055 - 1060
[26] Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
Huang, YeXing
Du, ZeFeng
Kan, Anna
He, MinKe
Li, HuiFang
Lai, ZhiCheng
Wen, DongSheng
Huang, LiChang
Li, QiJiong
Xu, Li
Shi, Ming
FRONTIERS IN IMMUNOLOGY, 2024, 15
[27] PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
Huang, Zhenkun
Chen, Tiejun
Li, Wenbin
Qiu, Jiliang
Liu, Shaoru
Wu, Zongfeng
Li, Binkui
Yuan, Yunfei
He, Wei
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
[28] Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
Li, Xiaocheng
Jiang, Zhiyang
Wu, Yongjuan
Gong, Wei
Liao, Xiaofeng
Li, Xiaogang
FRONTIERS IN ONCOLOGY, 2022, 12
[29] Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics
Metzger, Philipp
Sonega, Fabiane
Berthomme, Herve
Obodozie, Cynthia
Weber, Holger
CANCER RESEARCH, 2023, 83 (07)
[30] Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world study
Dai, B.
Dong, Z.
Sui, C.
Wang, K.
Geng, L.
ANNALS OF ONCOLOGY, 2024, 35 : S667 - S667

← 1 2 3 4 5 →